| scholarly article | Q13442814 |
| P356 | DOI | 10.1053/J.AJKD.2009.12.039 |
| P8608 | Fatcat ID | release_sjnbpqwgcjdmnij3ptv42m5huy |
| P698 | PubMed publication ID | 20347511 |
| P2093 | author name string | Peter G Kerr | |
| Boyd J Strauss | |||
| Kevan R Polkinghorne | |||
| Kenneth K Lau | |||
| Nigel D Toussaint | |||
| P433 | issue | 1 | |
| P921 | main subject | vascular calcification | Q54911504 |
| P304 | page(s) | 57-68 | |
| P577 | publication date | 2010-03-29 | |
| P1433 | published in | American Journal of Kidney Diseases | Q4744250 |
| P1476 | title | Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial | |
| P478 | volume | 56 |
| Q37614180 | A comparison of calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD. |
| Q27002431 | Are there ways to attenuate arterial calcification and improve cardiovascular outcomes in chronic kidney disease? |
| Q39071314 | Arterial Calcification in Diabetes Mellitus: Preclinical Models and Translational Implications. |
| Q38543758 | Arteriosclerosis and vascular calcification: causes, clinical assessment and therapy |
| Q34162996 | Association of warfarin use with valvular and vascular calcification: a review. |
| Q54313739 | Bisphophonates in CKD patients with low bone mineral density. |
| Q87389408 | Bisphosphonate safety and efficacy in chronic kidney disease |
| Q33571790 | Bisphosphonates and mortality in women with CKD and the presence or absence of cardiovascular disease |
| Q35462296 | Bisphosphonates and risk of cardiovascular events: a meta-analysis |
| Q44657342 | Bisphosphonates, atherosclerosis and vascular calcification: update and systematic review of clinical studies |
| Q37832414 | Can bisphosphonates play a role in the treatment of children with chronic kidney disease? |
| Q90399739 | Cardiovascular Calcification in Chronic Kidney Disease-Therapeutic Opportunities |
| Q88814822 | Chronic kidney disease: KDIGO CKD-MBD guideline update: evolution in the face of uncertainty |
| Q37322136 | Lowering vascular calcification burden in chronic kidney disease: Is it possible? |
| Q87900128 | Management of Osteoporosis in CKD |
| Q28087423 | Molecular Mechanisms of Vascular Calcification in Chronic Kidney Disease: The Link between Bone and the Vasculature |
| Q39255870 | Osteoporosis, bone mineral density and CKD-MBD: treatment considerations. |
| Q38458773 | Pharmacology of Bisphosphonates in Patients with Chronic Kidney Disease |
| Q35247898 | Recent progress in the treatment of vascular calcification |
| Q59126536 | Rethinking Bone Disease in Kidney Disease |
| Q33779709 | Skeletal effects of zoledronic acid in an animal model of chronic kidney disease |
| Q88672806 | The Role of Vascular Calcification in Heart Failure and Cognitive Decline |
| Q55521846 | The relationship between poor nutritional status and progression of aortic calcification in patients on maintenance hemodialysis. |
| Q38150099 | Therapy for patients with CKD and low bone mineral density |
| Q57796694 | Updates in CKD-Associated Osteoporosis |
| Q38671493 | Vascular Calcification in Uremia: New-Age Concepts about an Old-Age Problem |
| Q59100578 | Vascular calcification and renal bone disorders |
| Q37195354 | Vascular calcification in chronic kidney disease: Pathogenesis and clinical implication |
| Q53527834 | Vascular calcification in chronic kidney disease: an update. |
| Q38754124 | Vascular calcification in type-2 diabetes and cardiovascular disease: Integrative roles for OPG, RANKL and TRAIL. |
| Q28071582 | Vascular calcification: When should we interfere in chronic kidney disease patients and how? |
| Q38086058 | Vascular calcification: an update on mechanisms and challenges in treatment |
Search more.